Business Wire

TX-DENTALMONITORING

4.10.2021 16:09:05 CEST | Business Wire | Press release

Share
DentalMonitoring Launches the ScanBoxpro, the New Version of Their Patented Device to Maximize AI-powered Control of Dental and Orthodontic Care Anywhere, Anytime

DentalMonitoring, the company that pioneered artificial intelligence in dental and orthodontic care, is thrilled to announce the launch of the ScanBoxpro .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005610/en/

Built upon the success of their previous DM ScanBox, their latest FDA-registered innovation is a portable device patients can take with them for precise AI-powered scans anywhere and anytime. This hardware accompanies the flagship software solution DentalMonitoring, a customizable cloud-based platform for remote clinical monitoring of orthodontic treatments designed to create a single automated workflow per patient and boost practice scalability.

The device consists of two components — a cheek retractor tube designed to draw the cheeks and lips from the buccal and labial surfaces of the teeth and gums during scanning and a phone holder designed to accommodate a smartphone.

Paired with the unique DM app for patients, the ScanBoxpro offers:

  • Consistent imaging over time for precise tracking of treatment progress including aligners, braces and retainers of all brands
  • Excellent occlusal and lateral views, including molar occlusion
  • Increased portability
  • Suited for all patients from 6 years old.
  • Easy storage capability with 41% less volume
  • Autoclavable capacity

“We couldn’t be prouder to introduce our latest innovation as we continue to go further and break new ground with our solutions,” says Phillipe Salah, CEO of DentalMonitoring. “The ScanBoxpro is a game-changer for patients. It’s lightweight, portable and can easily join them on-the-go, anywhere, for high-quality scans powered by the first and most robust AI in the industry. In turn, it allows doctors to have control at every stage of treatment and helps automate their workflow while enhancing their patient experiences.”

The ScanBoxpro is the newest addition to DentalMonitoring’s family of devices and software solutions including SmileMate, for engagement, triage and patient conversion and DentalMonitoring, the only available AI-based remote monitoring solution available to both fixed and removable orthodontic appliances of all brands.

About DentalMonitoring

DentalMonitoring was started with a simple idea: oral care should be connected and continuous — even outside the practice. Since then, the company has developed cutting edge algorithms based on the industry's largest image database that perform high-level AI analysis, calculate tooth movement remotely, and create photo-realistic simulations.
Their suite of solutions is a fully scalable, AI-powered platform giving providers the insights needed to modernize dental care. Backed by the industry’s largest AI database, the platform and patented technology allows doctors to detect and monitor oral observations remotely, optimizing in-person appointments. Smarter remote care breaks barriers to treatment for patients, and practices can broaden their presence with smarter care.

More information: www.dental-monitoring.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 13:05:00 CEST | Press release

Dr. Zhaohui Su and Dr. Gil Fine deepen Veristat’s biostatistics expertise, Scott Tarrant leads Strategic Drug Development Advisory, and Clint Wolfe joins as Chief Human Resources Officer VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe

Bacardi Takes Full Ownership of TEELING® Irish Whiskey23.6.2026 13:00:00 CEST | Press release

Irish whiskey brand joins family-owned company’s portfolio of premium brands Bacardi Limited has announced the completion of a transaction that makes the family-owned company the sole owner of the Teeling Whiskey Company and the TEELING® Irish whiskey brand. Founders Jack and Stephen Teeling will remain a part of the brand, shaping its future and driving growth for the long term as strategic advisors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623858211/en/ Three expressions of Teeling Irish Whiskey: Single Grain, Small Batch and Single Malt Today’s announcement follows the successful relationship the two companies have enjoyed since Bacardi acquired a minority stake in the Dublin-based whiskey company in 2017. Bacardi subsequently increased its stake to become the majority shareholder in 2022. “TEELING is the perfect fit for Bacardi,” says Mahesh Madhavan, Chief Executive Officer, Bacardi Limited. “The brand stands f

Bending Spoons S.p.A. announces launch of initial public offering23.6.2026 12:15:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the launch of its initial public offering (the “IPO”) of its ordinary shares. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 are being offered by Bending Spoons and 23,572,375 are being offered by certain selling shareholders (the “Selling Shareholders”). In connection with the offering, Bending Spoons and the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and an additional 3,451,626 ordinary shares from the Selling Shareholders at the IPO price, less underwriting discounts and commissions. The IPO price is currently estimated to be between $26.00 and $28.00 per share. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint l

WSJ Intelligence Study: Uniquely Human Skills Deemed "Non-Replicable" in Automated Future23.6.2026 12:00:00 CEST | Press release

Philip Morris International and WSJ Intelligence reveal a "Human Premium" in the AI era, warning of cognitive atrophy risks alongside rapid corporate automation Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today revealed topline findings from a forthcoming study at Journal House during the Cannes Lions International Festival of Creativity. The study delivered a clear takeaway for global businesses: human cognition must be the absolute forefront of the modern corporate landscape. The findings show that uniquely human skills are vital, non-replicable, and increasingly valuable in an AI-embedded future, with creative empathy and critical thinking among the most distinctive workplace advantages. Surveying over 2,500 business professionals across the United States, United Kingdom, Italy, South Africa and Brazil, the joint initiative is the largest-scale research pro

Bitcoin Suisse Receives MiCAR License and Launches European Expansion23.6.2026 11:37:00 CEST | Press release

The Liechtenstein Financial Market Authority has granted Bitcoin Suisse (Europe) AG a license as a Crypto Asset Service Provider (CASP) under MiCAR. The European entity of Bitcoin Suisse can now serve clients across selected EEA markets, with Roman Przibylla appointed CEO to lead the expansion. After more than a decade as Switzerland's crypto pioneer, the Bitcoin Suisse Group ("Bitcoin Suisse") is expanding across Europe. Its European entity, Bitcoin Suisse (Europe) AG, founded in 2018, has been granted a license as a Crypto Asset Service Provider (CASP) under MiCAR by the Liechtenstein Financial Market Authority (FMA), building on its long-standing registration under the Token and TT Service Provider Act (TVTG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622188006/en/ left: Andrej Majcen, Co-Founder and Group CEO of the Bitcoin Suisse Group; right: Roman Przibylla, CEO of Bitcoin Suisse (Europe) AG Across Europe, Bit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye